Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (71)

« Back to Publications

Lenacapavir: Patient and healthcare provider perceptions and the potential role for a twice-yearly injectable HIV treatment.

Alford K. et al, (2025), HIV Med, 26, 441 - 450

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV.

Cargill T. et al, (2023), JHEP Rep, 5

Re-valuation of annual cytology using HPV self-sampling to upgrade prevention (REACH UP): A feasibility study in women living with HIV in the UK.

Cicconi P. et al, (2022), HIV Med, 23, 390 - 396

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

EWER K. et al, (2021), The Lancet

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

HODGSON S., (2020), The Lancet

MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.

Esposito I. et al, (2020), Sci Transl Med, 12

First-in-human randomized study to assess the safety and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine based on ChAd155 viral vector expressing RSV viral proteins F, N and M2-1 in healthy adults

SNAPE M. et al, (2019), Clinical Infectious Diseases

MHC-II invariant chain adjuvanted chimpanzee adenoviral and MVA hepatitis C vaccines elicit unprecedented levels of anti-viral T-cell immune responses in humans

Esposito I. et al, (2019), JOURNAL OF HEPATOLOGY, 70, E3 - E4

Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016.

Rossetti B. et al, (2018), HIV Med, 19, 619 - 628

Identification of novel resistance associated substitutions for sofosbuvir in HCV genotype 3a

Smith D. et al, (2018), JOURNAL OF HEPATOLOGY, 68, S269 - S269

A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.

Hartnell F. et al, (2018), Front Immunol, 9

Pathophysiology of ischaemic heart disease.

Pocock MO. et al, (2017), Current opinion in HIV and AIDS, 12, 548 - 553

Brief Report: Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort.

Vita S. et al, (2017), J Acquir Immune Defic Syndr, 74, 347 - 352

Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients.

Lichtner M. et al, (2015), J Infect Dis, 211, 178 - 186

Load More

1
2
3
4
5